Stock Analysts’ updated eps estimates for Thursday, May 16th:

A.G. Barr (LON:BAG) had its house stock rating reiterated by analysts at Shore Capital.

Brightcove (NASDAQ:BCOV) had its buy rating reaffirmed by analysts at Northland Securities. They currently have a $14.00 price target on the stock.

Countryside Properties (LON:CSP) had its not rated rating reaffirmed by analysts at Shore Capital.

1&1 Drillisch (ETR:DRI) had its neutral rating reiterated by analysts at DZ Bank AG.

Eiger Biopharmaceuticals (NASDAQ:EIGR) had its buy rating reissued by analysts at Wedbush. The firm currently has a $35.00 price target on the stock.

Bilfinger (ETR:GBF) had its buy rating reaffirmed by analysts at DZ Bank AG.

Horizonte Minerals (LON:HZM) had its not rated rating reaffirmed by analysts at Shore Capital.

Berenberg Bank began coverage on shares of LivePerson (NASDAQ:LPSN). Berenberg Bank issued a buy rating and a $40.00 price target on the stock.

Mirati Therapeutics (NASDAQ:MRTX) had its hold rating reiterated by analysts at Cantor Fitzgerald. The analysts wrote, “. We reiterate our Neutral rating and 12-month price target of $66 on MRTX. This evening, ASCO abstracts for oral and poster presentations were published online that included Amgen’s (N, covered by A. Young) first clinical data from its KRASi AMG510, which is a potential read to Mirati’s MRTX849. Overall, early AMG510 data seem to be still preliminary, and full data at ASCO (6/3) will remain a key investor focus to assess single-agent vs. combo strategy, in our view. We have provided more detailed color on pgs. 2-5. Amgen’s KRASi AMG510 early data in abstract still preliminary. In the dose- escalation stage, AMG510 reported 1 confirmed PR (11% ORR) from 9 evaluable patients (of total 22 pts.).””

Matinas BioPharma (NYSEAMERICAN:MTNB) had its buy rating reissued by analysts at Maxim Group. Maxim Group currently has a $5.00 target price on the stock. The analysts wrote, “Matinas reported 1Q19 with a net loss of ($4.3M) and cash of $39.4M. This included a $32.4M financing completed in March, which should provide funding into 2021.””

Oracle Power (LON:ORCP) had its not rated rating reiterated by analysts at Shore Capital.

CIBC initiated coverage on shares of Outlook Therapeutics (NASDAQ:OTLK). CIBC issued an outperform rating and a $12.00 price target on the stock.

QuinStreet (NASDAQ:QNST) had its buy rating reiterated by analysts at Barrington Research. They currently have a $20.00 price target on the stock.

Wincanton (LON:WIN) had its not rated rating reissued by analysts at Shore Capital.

Receive News & Ratings for AG Barr plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AG Barr plc and related companies with MarketBeat.com's FREE daily email newsletter.